News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Burnout: Which Way Out?

April 25, 2023
Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 37, Issue 4
Volume 37
Issue 4
Pages: 161

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the effects and prevalence of burnout amongst oncologists and reviews strategies to address the issue.

Burnout and the related morale injury it causes are characterized by physical and/or emotional exhaustion, depersonalization, and decreased effectiveness. Burnout is all too common in physicians and is estimated to affect at least 50% of physicians at some point in their career.1 Many systemic risk factors contribute to this epidemic, including high patient volumes, increased administrative burden, lack of “user-friendly” electronic medical records, and lack of organizational infrastructure. Personal risk factors include being female, not having a spouse or partner, and being of younger age.

Oncologists are particularly at risk for burnout due to the difficult patient population we treat, continuous exposure to life-threatening illnesses, and psychological distress.

By now we can all identify burnout and stress. The more important question is what to do about it. Physician wellness starts with us: getting the rest we need, eating a healthy diet, exercising, doing activities that are not work related, and identifying and reducing unnecessary stress. The harder part is, how can we get the health care system to recognize stress in physicians and work with us on modifications to decrease the stress and burnout?

There is only so much any 1 physician can do on their own to reduce stress without infrastructure modifications. Research comparing the effectiveness of individual vs organizational interventions suggests that institutional interventions are much more effective than individual approaches alone, but both approaches when used together are the most effective in reducing burnout.2

How can health care professionals improve the systemic infrastructure that contributes to burnout? We need to work with the health care organization to build system-level interventions aimed at reducing environmental stressors and improve the workplace infrastructure support. One example of a program with such a design is the University of Colorado APEX (Awesome Patient Experience) teamwork model, which incorporates medical assistants to decrease administrative burdens on providers. After this system was implemented, the physician burnout rate was reduced from 53% to 13%.3

In addition, a thorough evaluation of the necessity of all online learning modules and excess meetings and committees and a reevaluation of patient volumes per provider are needed to move toward the future. Another example of an available program to help institutions is the American Medical Association STEPS Forward.4 This program recommends 9 strategies—engagement of leadership, acknowledgment and routine of longitudinal burnout assessments, creation of infrastructure for implementation of individual and system-level interventions, workflow efficiency, reduction in administrative burdens, support for the health of the workforce, strengthening of local leadership, tracking organizational costs of burnout, and routine assessment of interventions—to promote organizational health and employee well-being.

The most important aspect of improving burnout is for physicians to work with the administrative and health care teams and to advocate for themselves. Medicine is a team sport, and all the players need to work together for the same goal.

REFERENCES

  1. Shanafelt TD, West CP, Sinsky C, et al. Changes in burnout and satisfaction with work-life integration in physicians and the general US working population between 2011 and 2017. Mayo Clin Proc. 2019;94(9):1681-1694. doi:10.1016/j. mayocp.2018.10.023
  2. Panagioti M, Panagopoulou E, Bower P, et al. Controlled interventions to reduce burnout in physicians: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(2):195-205. doi:10.1001/ jamainternmed.2016.7674
  3. Wright AA, Katz IT. Beyond burnout - redesigning care to restore meaning and sanity for physicians. N Engl J Med. 2018;378(4):309-311. doi:10.1056/ NEJMp1716845
  4. Redesign your practice: reignite your purpose. AMA Ed Hub. STEPS Forward. Accessed March 17, 2023. https://bit.ly/3YQq4z2
Download Issue PDFDownload PDF
Articles in this issue

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma
Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma
Advancement Continues in ‘Go-to’ Strategies for Gynecologic Cancer
Advancement Continues in ‘Go-to’ Strategies for Gynecologic Cancer
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
The Management of Relapsed and Refractory Multiple Myeloma
The Management of Relapsed and Refractory Multiple Myeloma
Burnout: Which Way Out?
Burnout: Which Way Out?
Related Videos
Related Content

Spinal ATRT and Radiotherapy Case Report in an Adult Man

September 21st 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

September 18th 2023

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019

Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL

September 16th 2023

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

September 15th 2023

Spinal ATRT and Radiotherapy Case Report in an Adult Man

September 21st 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

September 18th 2023

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019

Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL

September 16th 2023

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

September 15th 2023

Spinal ATRT and Radiotherapy Case Report in an Adult Man

September 21st 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

September 18th 2023

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019

Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL

September 16th 2023

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

September 15th 2023
Related Content
Advertisement

Spinal ATRT and Radiotherapy Case Report in an Adult Man

Spinal ATRT and Radiotherapy Case Report in an Adult Man

September 21st 2023
Article

A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

Assessing Cytokine Release Syndrome After Treatment With Teclistamab in Multiple Myeloma

September 18th 2023
Article

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL

Acalabrutinib and Zanubrutinib Display Similar Efficacy Results in R/R CLL

September 16th 2023
Article

Ryan Jacobs, MD, and Alan Pierre Zausner Skarbnik, MD, discussed the use of acalabrutinib and zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.


Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

Teclistamab Reviewed as Potential Treatment Option in Relapsed/Refractory Multiple Myeloma

September 15th 2023
Article

CancerNetwork hosted a Training Academy focused on sequencing therapies for patients with multiple myeloma who are treated with bispecific antibodies.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.